T. Coates

A multicenter clinical trial of gadolite oral suspension as a contrast agent for MRI

N. Rofsky, F. Shellock, E. Zerhouni, 1997, Journal of magnetic resonance imaging : JMRI.

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Steve B Jones, K. Y. Wong, Chamil H. Hettiarachchi, 2021, Lancet.

P1518: LONG-TERM SAFETY RESULTS OF THE BELIEVE STUDY OF LUSPATERCEPT IN ADULTS WITH ΒETA-THALASSEMIA

M. Cappellini, V. Viprakasit, A. Piga, 2022, HemaSphere.

S270: LONGER-TERM ANALYSIS OF EFFICACY OF LUSPATERCEPT VERSUS PLACEBO IN PATIENTS WITH TRANSFUSION-DEPENDENT BETA-THALASSEMIA ENROLLED IN THE BELIEVE STUDY

M. Cappellini, V. Viprakasit, A. Piga, 2022, HemaSphere.

A study protocol for a retrospective cohort study and interrupted time series analysis to assess the effect of the COVID-19 pandemic on major trauma presentations and patient outcomes in English hospitals.

O. Bouamra, F. Lecky, D. Yates, 2022, medRxiv.

A Randomized, Controlled Phase II Trial in Sickle Cell Disease Patients with Chronic Iron Overload Demonstrates That the Once-Daily Oral Iron Chelator Deferasirox (Exjade ® , ICL670) Is Well Tolerated and Reduces Iron Burden.

P. Marks, O. Onyekwere, P. Swerdlow, 2005 .

Satisfaction and Convenience of Chelation Therapy in Patients with Sickle Cell Disease (SCD): Comparison between Deferasirox (Exjade ® , ICL670) and Deferoxamine (DFO).

P. Marks, O. Onyekwere, P. Swerdlow, 2005 .